key: cord-0910553-5km3t92f
authors: Robinson, Dean P.; Smith, Alexander E.; Okiror, Lawrence
title: Lung Cancer Surgery in the early phase after acute COVID-19 pneumonitis
date: 2021-07-01
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2021.06.016
sha: e6cdb0a338eafe60183c519a2376cee5522aaee8
doc_id: 910553
cord_uid: 5km3t92f

A 65-year-old female was diagnosed with early-stage lung cancer in 2020 and scheduled for robotic assisted left upper lobectomy. Unfortunately, the patient contracted symptomatic COVID-19, resulting in postponement of lung resection. 6 weeks following acute infection she was admitted for surgery. A pre-operative computed tomography scan showed widespread interstitial pneumonitis. However, the surgery went ahead given concerns over tumour progression, albeit with a lesser resection to preserve lung tissue as the patient was slightly hypoxic. Her postoperative recovery was uneventful and she was discharged 5 days later. Final histology confirmed a fully resected stage T1cN0M0 adenocarcinoma of the lung.

Since, the arrival of the COVID-19 in the U.K. there have been over 4.3 million cases identified [1] .

This has mounted extreme pressure on the National Health Service and has led to severe bed shortages and cancelled elective surgeries. As of today, 10 million people are awaiting surgical procedures in the U.K., an increase from 4 million before the pandemic [2] . Waiting times for elective surgery are now at their highest, with the focus now on restoring services to pre-pandemic levels.

Currently there are no guidelines regarding the timing of thoracic surgery after an acute infection in the United Kingdom. As the number of post-COVID-19 patients requiring thoracic surgery increases, guidelines outlining recommended timeframes for surgery after infection will become more crucial. We present a case of a successful pulmonary left upper division segmentectomy 6 weeks following acute COVID-19 infection in a 65-year-old lady.

The case patient presented to her general practitioner (GP) with a 3-week history of a persistent cough. The patient was a recent ex-smoker. A chest X-ray was ordered by the GP which identified an abnormality in the left upper zone (Figure 1 ). Upon referral to the thoracic surgical unit, a computed tomography (CT) scan and a positron emission tomography scan showed a 2cm Fludeoxyglucose-avid lesion in the left upper lobe ( Figure 2 ). The standardised uptake value of the lesion was 14. Given the early staging of the tumour, the patient was scheduled for a left robotic-assisted upper lobectomy to take place in January 2021. Spirometry showed her forced expiratory volume in 1 second to be 1.6 litres (75% of predicted), forced vital capacity 2.2 litres, (87% predicted) and transfer factor to be 5.5 mmol/min/kPa (77% of predicted).

Unfortunately, the patient contracted symptomatic COVID-19 (confirmed on pre-operative polymerase chain reaction (PCR) testing) prior to admission and therefore her operation was postponed. She had not yet been vaccinated. Thankfully, admission to hospital was not required and the patient was managed in the community albeit with significant shortness of breath. Several weeks after the acute COVID-19 infection, the patient was still breathless, however she mentioned that this Post-operatively, the patient received aggressive physiotherapy and high flow nasal oxygen to aid with sputum expectoration. A chest drain was removed on day 2 after the operation. The patient later developed a hospital acquired pneumonia and was commenced on intra-venous co-amoxiclav. Her inflammatory markers continued to improve, and she was discharged on oral antibiotics on day 5 after surgery. She continues to make an excellent post-operative recovery at home with no further complications.

With the COVID-19 pandemic continuing, it is inevitable that a greater number of post-COVID-19 patients will require surgery. Additionally, COVID-19 infection can lead to pulmonary complications that require thoracic intervention, thus further increasing surgical demand during this pandemic [3] . As it currently stands, there are no official guidelines that describe the optimum timing of elective cancer surgery after symptomatic COVID-19 infection. Instead, research up to now suggests that surgery J o u r n a l P r e -p r o o f should be delayed arbitrarily or replaced with non-surgical management [4] but as restrictions on elective surgery are lifted, it will become more commonplace to assess post-COVID-19 patients' suitability for surgery.

Non-small cell lung cancer (NSCLC) remains, by far, the biggest cause of cancer deaths globally.

Surgery is the most efficacious treatment with excellent outcomes, particularly, in patients with stage I disease. Patients undergoing lung resection for NSCLC routinely undergo lung function testing to assess for fitness, tailor the extent of lung resection and stratify risk of postoperative complications, breathlessness and death [5] . COVID pneumonitis causes significant acute and often long-term hypoxia, breathlessness and lung scarring. A fine balance must be made between offering lungsparing surgery while maintaining adequate tumour clearance using anatomical lung resection which is the gold-standard surgical treatment for NSCLC. We decided to perform lingular-sparing surgery in this patient to reduce the risk of significant postoperative pulmonary complications and breathlessness.

Multiple previous studies have highlighted the increased risk of post-operative pulmonary complications and higher mortality rates after a COVID-19 infection [3] [4] with one study demonstrating a mortality rate of 20.5% after surgery with a concurrent COVID-19 infection and 44.1% of patients requiring intensive care unit level care [6] . The rates of post-operative pulmonary complications have been shown to be around 50% with mortality rates also much greater in patients with COVID-19 [4] . On the converse, a large cohort study of 40 000 people found that delaying surgery by 8 weeks for stage 1 NSCLC was associated with pathological upstaging of the tumour, a greater 30-day mortality and a decreased median survival [7] . It is therefore essential that we time surgery on the balance of the severity of post-COVID-19 complications against the risk of disease progression to produce the safest outcomes for patients. One study has suggested that surgery should be delayed by a minimum of 7 weeks after an acute COVID-19 infection to prevent against such J o u r n a l P r e -p r o o f complications [8] . However, we present a case of a successful and uncomplicated left upper segmentectomy in a patient with significant COVID-19 pneumonitis in a shorter timeframe.

To conclude, we present a successful case of anatomical lung resection in a 65-year-old lady 6 weeks after acute COVID-19 pneumonitis. This case highlights the importance of balancing the risk of disease progression against the patient's comorbid status and clinical condition. Uncomplicated thoracic surgical intervention is possible, even with ongoing radiographic evidence of pneumonitis.

Further studies are required to delineate the optimal timing of surgery during this pandemic. 

Coronavirus (COVID-19) in the UK

Too long to wait: the impact of COVID-19 on elective surgery

Thoracic surgery outcomes for patients with

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Guidelines on the radical management of patients with lung cancer

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Effects of delayed surgical resection on short-term and longterm outcomes in clinical stage I Non-small cell lung cancer